Float Short %

12.16

Margin Of Safety %

-38

Put/Call OI Ratio

0.05

EPS Next Q Diff

-0.42

EPS Last/This Y

-1.01

EPS This/Next Y

-0.01

Price

7.08

Target Price

7.57

Analyst Recom

Performance Q

129.77

Relative Volume

2.17

Beta

2.41

Ticker: FULC

19 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-06-02	FULC	6.95	0.05	2.48	8321
2025-06-03	FULC	7.03	0.06	999.99	8436
2025-06-04	FULC	7.02	0.06	0.25	8436
2025-06-05	FULC	7.11	0.06	0.00	8438
2025-06-06	FULC	7.24	0.06	0.00	8444
2025-06-09	FULC	7.12	0.06	0.16	8448
2025-06-10	FULC	6.9	0.06	0.03	8585
2025-06-11	FULC	6.82	0.06	0.03	8585
2025-06-12	FULC	6.78	0.06	0.03	8585
2025-06-13	FULC	6.85	0.06	0.00	8607
2025-06-16	FULC	6.81	0.06	0.00	8607
2025-06-17	FULC	6.44	0.06	999.99	8628
2025-06-18	FULC	6.36	0.06	0.00	8629
2025-06-20	FULC	7	0.06	0.23	8635
2025-06-23	FULC	7.18	0.04	0.08	7553
2025-06-24	FULC	7.18	0.05	0.05	7886
2025-06-25	FULC	7.16	0.05	0.33	7934
2025-06-26	FULC	7.39	0.05	0.17	7936
2025-06-27	FULC	7.08	0.05	0.05	8139
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-06-02	FULC	6.95	-133.8	-	-1.17
2025-06-03	FULC	7.03	-133.8	-	-1.17
2025-06-04	FULC	7.02	-133.8	-	-1.17
2025-06-05	FULC	7.11	-133.8	-	-1.17
2025-06-06	FULC	7.24	-133.8	-	-1.17
2025-06-09	FULC	7.12	-133.8	-	-1.17
2025-06-10	FULC	6.90	-133.8	-	-1.17
2025-06-11	FULC	6.82	-133.8	-	-1.17
2025-06-12	FULC	6.78	-133.8	-	-1.17
2025-06-13	FULC	6.85	-133.8	-	-1.17
2025-06-16	FULC	6.80	-133.8	-	-1.17
2025-06-17	FULC	6.46	-133.8	-	-1.17
2025-06-18	FULC	6.36	-133.8	-	-1.17
2025-06-20	FULC	6.99	-133.8	-	-1.17
2025-06-23	FULC	7.18	-133.8	-	-1.17
2025-06-24	FULC	7.18	-133.8	-	-1.17
2025-06-25	FULC	7.16	-133.8	-	-1.17
2025-06-26	FULC	7.38	-133.8	-	-1.17
2025-06-27	FULC	7.08	-133.8	-	-1.17
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-06-02	FULC	-0.01	-1.51	10.30
2025-06-03	FULC	-0.01	-1.51	10.30
2025-06-04	FULC	-0.01	-1.51	10.30
2025-06-05	FULC	-0.01	-1.51	10.30
2025-06-06	FULC	-0.01	-1.51	10.30
2025-06-09	FULC	-0.01	-1.52	10.30
2025-06-11	FULC	-0.01	-1.52	11.87
2025-06-12	FULC	-0.01	-1.52	11.87
2025-06-13	FULC	-0.01	-1.52	11.87
2025-06-16	FULC	-0.01	-1.56	11.87
2025-06-17	FULC	-0.01	-1.56	11.87
2025-06-18	FULC	-0.01	-1.56	11.87
2025-06-19	FULC	-0.01	-1.56	11.87
2025-06-20	FULC	-0.01	-1.56	11.87
2025-06-24	FULC	-0.01	-1.40	11.87
2025-06-25	FULC	-0.01	-1.40	11.87
2025-06-26	FULC	-0.01	-1.40	12.16
2025-06-27	FULC	-0.01	-1.40	12.16
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.28

Avg. EPS Est. Current Quarter

-0.29

Avg. EPS Est. Next Quarter

-0.7

Insider Transactions

-0.01

Institutional Transactions

-1.4

Beta

2.41

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

4.39

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

78.6

Max Drawdown 5-Year %

-92.7

Target Price

7.57

P/E

Forward P/E

PEG

P/S

4.79

P/B

1.68

P/Free Cash Flow

50.7

EPS

-0.07

Average EPS Est. Cur. Y

-1.17

EPS Next Y. (Est.)

-1.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-0.64

Relative Volume

2.17

Return on Equity vs Sector %

-24.1

Return on Equity vs Industry %

-6.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Fulcrum Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 45

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

stock quote shares FULC – Fulcrum Therapeutics Inc Stock Price stock today

news today FULC – Fulcrum Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch FULC – Fulcrum Therapeutics Inc yahoo finance google finance

stock history FULC – Fulcrum Therapeutics Inc invest stock market

stock prices FULC premarket after hours

ticker FULC fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: FULC

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y